HORN HOWARD (Chief Financial Officer) sold 10.6% of their position (10.04K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $227.5K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/3/2026ACC: 0001193125-26-089107
Officer· Chief Financial Officer
Since Mar 2026
-3.90K
Net shares
Net seller
$227.5K
Total sold
3
Open market trades
0B · 3S
4
Total transactions
6.14K acquired · 10.04K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+6.14K
Price / share
—
Trade value
—
% of position
6.9%
3/1/2026
88.94K→95.08K
Common Stock
Direct
Shares
−5.29K
Price / share
$22.80
Trade value
$120.61K
% of position
5.6%
3/2/2026
95.08K→89.79K
Common Stock
Direct
Shares
−3.12K
Price / share
$22.54
Trade value
$70.30K
% of position
3.5%
3/2/2026
89.79K→86.67K
Common Stock
Direct
Shares
−1.64K
Price / share
$22.40
Trade value
$36.62K
% of position
1.9%
3/3/2026
86.67K→85.03K
Total
Net shares
−3.90K
Net value
-$227.54K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/1/2026 | A · Award | +6.14K | — | — | 6.9% | 88.94K | 95.08K |
| Common Stock Direct | 3/2/2026 | S · Sale | −5.29K | $22.80 | $120.61K | 5.6% | 95.08K | 89.79K |
| Common Stock Direct | 3/2/2026 | S · Sale | −3.12K | $22.54 | $70.30K | 3.5% | 89.79K | 86.67K |
| Common Stock Direct | 3/3/2026 | S · Sale | −1.64K | $22.40 | $36.62K | 1.9% | 86.67K | 85.03K |
| Total | −3.90K | -$227.54K | ||||||
Derivative Transactions0
No derivative transactions reported